Journal of Skin Cancer最新文献

{"title":"Oral Nicotinamide for the Secondary Prevention of Cutaneous Squamous Cell Carcinoma and Other Keratinocyte Carcinomas: A Systematic Review.","authors":"Andrea Lizeth Guerra Jiménez, Juan Carlos Ortegón Garciaherreros, Lilia Patricia Suárez Escobar, Laura Valentina Vargas Monroy, María Camila Madariaga Estupiñán","doi":"10.1155/jskc/8756577","DOIUrl":"https://doi.org/10.1155/jskc/8756577","url":null,"abstract":"<p><strong>Background: </strong>Oral nicotinamide has been proposed as a chemoprevention strategy to reduce new keratinocyte carcinomas in people with a history of skin cancer, but its effect may differ between immunocompetent patients and transplant recipients.</p><p><strong>Objective: </strong>To evaluate the effectiveness and safety of oral nicotinamide for the secondary prevention of cutaneous squamous cell carcinoma and other keratinocyte carcinoma-related outcomes in adults with a history of skin cancer.</p><p><strong>Methods: </strong>We conducted a systematic review following PRISMA 2020. We searched PubMed/MEDLINE, Embase, and LILACS through the Virtual Health Library from inception to May 30, 2026. We included comparative studies (randomized clinical trials and controlled nonrandomized studies) evaluating oral nicotinamide versus placebo, no treatment, usual care, or another preventive strategy. Risk of bias was assessed with RoB 2 for randomized trials and ROBINS-I for nonrandomized studies, and the certainty of evidence was assessed with GRADE. We performed a narrative synthesis and an exploratory random-effects meta-analysis of randomized trials when clinically appropriate; effect measures were rate ratios for randomized trials and hazard ratios for the observational cohort. Randomized and nonrandomized designs were not statistically pooled together.</p><p><strong>Results: </strong>We identified 1076 records; after removing 151 duplicates, 925 records were screened, 17 full texts were assessed, and 5 studies were included: 4 randomized clinical trials and 1 large retrospective cohort. In high-risk immunocompetent adults, the benefit signal was driven by a single pivotal randomized trial (ONTRAC; <i>n</i> = 386), in which nicotinamide reduced new nonmelanoma skin cancers (rate ratio, 0.77; 95% CI, 0.62-0.96). In transplant recipients, the main exploratory meta-analysis of two randomized trials (<i>n</i> = 180) showed no significant reduction in total keratinocyte carcinoma/nonmelanoma skin cancer (pooled rate ratio, 0.97; 95% CI, 0.77-1.22; <i>I</i> <sup>2</sup> = 0.0%), cSCC/SCC (0.90; 95% CI, 0.65-1.25; 2 trials), or basal cell carcinoma (0.80; 95% CI, 0.20-3.18; 2 trials). A large retrospective cohort (Breglio et al.; 33,822 patients) reported an overall 14% reduction in skin cancer (hazard ratio, 0.86; 95% CI, 0.83-0.89) that was greatest for cSCC and greatest when nicotinamide was started after the first skin cancer, but there was no overall benefit in transplant recipients (hazard ratio, 1.02; 95% CI, 0.84-1.25). Certainty was low or very low for the transplant-recipient outcomes.</p><p><strong>Conclusions: </strong>In high-risk immunocompetent adults, oral nicotinamide may reduce new nonmelanoma skin cancers during active treatment, but this conclusion rests predominantly on one large randomized trial and should be regarded as provisional. In transplant recipients, the randomized evidence does not demonstrate a significant bene","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2026 ","pages":"8756577"},"PeriodicalIF":0.9,"publicationDate":"2026-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13635799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149111347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Outcomes of Immune Checkpoint Inhibitors in Melanoma, Including Acral and Mucosal Subtypes: A Retrospective Cohort Study From a Latin American Center.","authors":"Vaneza Avila-Rodriguez, Juan Manuel Vasquez, Luisana Molina-Pimienta, Carlos Bonilla-Gonzalez, Julian Rondon-Carvajal, Sebastian Gil-Tamayo, Camilo Rueda, Andrea Russi, Ricardo Bruges","doi":"10.1155/jskc/3904810","DOIUrl":"10.1155/jskc/3904810","url":null,"abstract":"<p><strong>Background: </strong>Real-world evidence on immune checkpoint inhibitors (ICIs) in Latin American patients with melanoma remains limited, particularly for acral and mucosal subtypes. We evaluated survival, radiologic response, immune-related adverse events (irAEs), and exploratory factors associated with outcomes in a Colombian cohort.</p><p><strong>Methods: </strong>This single-center retrospective cohort included consecutive patients with histologically confirmed melanoma who received ≥ 1 ICI dose between February 2017 and November 2022. Patients were classified as adjuvant- or palliative-intent. rwOS and irAEs were assessed in the overall cohort; rwDFS in the adjuvant-intent cohort; and rwPFS and best radiologic response in the palliative-intent cohort. Survival was estimated using Kaplan-Meier methods, with median follow-up calculated by reverse Kaplan-Meier. Primary Cox proportional hazards analyses of rwPFS and rwOS were restricted to the palliative-intent cohort.</p><p><strong>Results: </strong>Fifty-seven patients were included: 20 received adjuvant- and 37 palliative-intent therapy. Median age was 65 years (IQR, 54-76); acral and mucosal melanoma accounted for 26 (45.6%) and 11 (19.3%) cases, respectively. Median follow-up was 32.3 months (95% CI, 25.9-42.3). In the adjuvant-intent cohort, median rwDFS and rwOS were 23.3 months (95% CI, 4.8-not reached) and 33.0 months (95% CI, 30.1-not reached), respectively. In the palliative-intent cohort, median rwPFS and rwOS were 8.5 months (95% CI, 6.0-24.1) and 26.0 months (95% CI, 17.9-not reached), respectively. Among 31 response-evaluable patients, ORR was 38.7% (95% CI, 23.7-56.2) and DCR was 54.8% (95% CI, 37.8-70.8). IrAEs were documented in 31 patients (54.4%); five had Grade 3 events, and no Grade 4 or five irAEs were documented. In adjusted models, ECOG performance status and melanoma subtype were not significantly associated with rwPFS or rwOS.</p><p><strong>Conclusions: </strong>ICIs demonstrated antitumor activity in this Colombian real-world cohort, including patients with acral and mucosal melanoma, although survival estimates were numerically lower than those reported in selected pivotal trials. Documented toxicity was predominantly low grade. Exploratory analyses suggested more favorable outcomes in patients with conventional cutaneous melanoma.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2026 ","pages":"3904810"},"PeriodicalIF":0.9,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13617541/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149075010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Melanoma Severity at Presentation and Prior Skin Cancer Screening: A Survey Study of Surgical Oncology Patients.","authors":"Arnar B Ingason, Venkatesa P Muruganandam, Melanie Bui, Jessica Cintolo-Gonzalez","doi":"10.1155/jskc/3520345","DOIUrl":"10.1155/jskc/3520345","url":null,"abstract":"<p><strong>Introduction: </strong>The effectiveness of population-based melanoma screening remains uncertain. However, most melanomas continue to present outside of skin cancer screening, underscoring the need to better understand and serve unscreened populations.</p><p><strong>Methods: </strong>All patients presenting to surgical oncology at a rural tertiary referral center with newly diagnosed invasive melanoma from April 2020 to January 2021 were administered a survey to assess history of a skin cancer screening examination and risk factors for melanoma. Additional demographic and clinical characteristics were abstracted from the electronic medical record. The exposure of interest was dermatological skin cancer screening examination within the past 12 months. The primary outcome was pathological tumor staging. This was assessed using ordinal logistic regression.</p><p><strong>Results: </strong>Forty patients presented to surgical oncology with a newly diagnosed melanoma. Thirty patients (75%) reported no skin cancer screening examination within the past 12 months. Patients who had screening were more likely to report prior indoor tanning use (70% [7/10] vs. 23% [7/30], OR 7.20, 95% CI 1.25-55.24, <i>p</i> = 0.02) and a personal history of nonmelanoma skin cancer (60% [6/10] vs. 13% [4/30], OR 9.00, 95% CI 1.44-68.66 <i>p</i> = 0.007). Remaining baseline characteristics were similar. Patients who had screening presented with a significantly lower T stage (OR 0.24, 95% CI 0.05-0.91, <i>p</i> = 0.04). No patients who had screening presented with lymph node metastasis compared with 20% of patients (6/30) who did not undergo screening. No patients in our cohort presented with distant metastasis.</p><p><strong>Conclusions: </strong>Most melanomas presenting to surgical oncology occurred in patients without recent screening and were more advanced at presentation. These findings highlight the importance of maintaining rapid access to dermatologic evaluation for patients who do not participate in routine screening, as they represent the majority of clinically significant melanoma presentations.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2026 ","pages":"3520345"},"PeriodicalIF":0.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575876/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148977205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative Margin Management After Conventional Excision of Facial Basal and Squamous Cell Carcinomas: A Histotype-Specific Framework.","authors":"Flavio Perottino, Stefano Ottoboni, Giulia Dalmasso, Katia Barbaro, Daniele Sagrafoli, Paola Ghisellini, Cristina Rando, Roberto Eggenhöffner, Mario Borgione","doi":"10.1155/jskc/9952281","DOIUrl":"10.1155/jskc/9952281","url":null,"abstract":"<p><strong>Background: </strong>Postoperative management of close or positive margins after conventional excision of facial nonmelanoma skin cancer is challenging, especially in elderly patients and anatomically constrained sites where re-excision may impose functional or aesthetic morbidity.</p><p><strong>Methods: </strong>We retrospectively analysed 238 facial carcinoma cases treated by conventional excision at a peripheral ENT unit, including 172 basal cell carcinomas (BCC) and 66 squamous cell carcinomas (SCC). Margins were classified as clear, close or positive. Outcomes were analysed descriptively; two-sided Fisher exact tests were used as exploratory descriptors of distributional imbalance under sparse-event conditions, not as tests of treatment superiority or equivalence.</p><p><strong>Results: </strong>In BCC, no recurrence occurred after clear margins (0/90). Among non-clear-margin BCCs, recurrence remained uncommon after structured surveillance (5/65) and early re-excision (1/17). In SCC, recurrence occurred only after positive margins (3/15), with none after clear or close margins.</p><p><strong>Conclusion: </strong>The findings support histotype-specific postoperative interpretation of margin status after conventional facial skin cancer excision. In this cohort, selected lower-risk BCC cases were managed through structured surveillance, whereas SCC recurrence was confined to positive-margin cases, supporting a lower threshold for timely re-excision or equivalent oncologic management when clinically feasible.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2026 ","pages":"9952281"},"PeriodicalIF":0.9,"publicationDate":"2026-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13522925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148850900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Response of Cemiplimab Immunotherapy for Treating Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma in a Tertiary UK Oncology Centre.","authors":"Sumbal Umar, Zarmeen Shahid, Micheal O'Cathail, M Ananth Sivanandan","doi":"10.1155/jskc/8993856","DOIUrl":"10.1155/jskc/8993856","url":null,"abstract":"<p><strong>Introduction: </strong>Cemiplimab has been licensed for use in the United Kingdom as the sole immunotherapy agent for first-line use in advanced cutaneous squamous cell carcinoma (a-cSCC). Given that previous clinical trials leading to the approval of cemiplimab had relatively small patient cohorts with relatively short follow-up periods, with a large proportion of patients who had received prior systemic treatment, this retrospective real-world study sought to add further insight into survival and toxicity in patients who exclusively had received first-line use of cemiplimab, as well as comparing response rates (RRs) based on primary site location.</p><p><strong>Methods: </strong>This retrospective study identified patients diagnosed with a-cSCC between 01/08/2019 and 31/03/2024 who received cemiplimab as first-line treatment at our institution. Data to enable response assessment and toxicity were collected and analyzed.</p><p><strong>Results: </strong>50 patients were identified with a mean age of 75 years (range: 44-94). 78% (<i>n</i> = 39) of the patients' primary lesion originated from the head and neck (H&N) region, whilst the remaining 22% (<i>n</i> = 11) had a primary lesion from other areas. No patients had received prior systemic treatment for a-cSCC. Overall, the disease control rate (DCR) was 74%, and the RR was 55.8% with complete response in 35% (<i>n</i> = 15), partial response in 21% (<i>n</i> = 9), and stable disease in 19% (<i>n</i> = 8). In patients with H&N primary site of disease, RR was 58.9% versus 27.2% in patients with non-H&N primary site of disease, with a <i>p</i> value of 0.027. The overall mean PFS for the study population was 27.3 months (95% CI: 21.2-33.5 months), with the median PFS not reached for the study duration. The median PFS for patients with H&N primary site of disease was not reached as compared to the median PFS of 4 months (95% CI: 2.2-5.7 months) for patients with non-H&N primary site of disease, with a <i>p</i> value of 0.049. The median OS for the study population was 34 months (95% CI: 15.4-52.5 months). Grade 3 toxicities were reported in 22% (<i>n</i> = 11) with no Grade 4 toxicites.</p><p><strong>Discussion: </strong>The use of cemiplimab as first-line treatment in a-cSCC demonstrates high efficacy and low rates of serious toxicity, which is especially reassuring in a patient cohort comprising of more elderly patients. The high complete RR seen in our patient cohort may reflect the exclusive first-line use of cemiplimab in our study, as per now established real-world practice in a-cSCC. Higher RRs and PFS are seen in patients with head/neck primary site of disease vs. non head/neck primary site, which should be evaluated further in future clinical trials.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2026 ","pages":"8993856"},"PeriodicalIF":0.9,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13455040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148706836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Five-Year Follow-Up of Patients With Histologically Aggressive Basal Cell Carcinoma Treated With Interferon.","authors":"Vladimir Sanchez Linares, Vicente Eloy Fardales Macías, Iraldo Bello Rivero","doi":"10.1155/jskc/8852284","DOIUrl":"10.1155/jskc/8852284","url":null,"abstract":"<p><strong>Background: </strong>Basal cell carcinomas (BCCs) with aggressive histology are infiltrative, destructive, aggressive, and metastatic tumors. Aggressive variants include morpheaform, infiltrative, metatypical or basosquamous, micronodular, and mixed subtypes. Selecting the appropriate treatment is crucial to eliminate this type of tumor and avoid complications such as mutilation and deformities when located in the facial region, as well as tumor recurrence. Interferons may represent a therapeutic option because of their curative potential and long-term cosmetic effects.</p><p><strong>Material and methods: </strong>A descriptive, longitudinal, observational case-series study was conducted, including patients with a histopathological diagnosis of aggressive BCC. Perilesional HeberFERON was administered for three weeks, and patients were then followed for 5 years. The main outcome variables were cure at 16 weeks and recurrence at 5 years.</p><p><strong>Results: </strong>Twenty-three patients were included, and one discontinued treatment. After therapy, 14 (63.6%) patients achieved cure (complete response [CR]). Those who did not achieve a CR underwent surgery and were declared cured. All 22 patients were followed for five years; two (9.0%) were lost to follow-up. Survival analysis showed that 86.4% (95% CI, 74%-99%) had the probability of remaining recurrence-free at five years.</p><p><strong>Conclusions: </strong>HeberFERON can be considered a first-line treatment for BCC with aggressive histology and as a therapy prior to subsequent surgery.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2026 ","pages":"8852284"},"PeriodicalIF":0.9,"publicationDate":"2026-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13312300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148352248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous Lymphomas and Lymphoproliferative Disorders Associated With SARS-CoV-2 Vaccination: A Systematic Review.","authors":"Martina Mussi, Corrado Zengarini, Alberto Corrà, Tullio Brunetti, Alessio Natale, Michelangelo La Placa, Bianca Maria Piraccini, Alba Guglielmo, Alessandro Pileri","doi":"10.1155/jskc/4893577","DOIUrl":"10.1155/jskc/4893577","url":null,"abstract":"<p><strong>Background: </strong>Cutaneous lymphomas (CLs) are rare neoplastic skin disorders, primarily of T-cell origin. Since the widespread rollout of SARS-CoV-2 vaccines, several cases of CLs and non-neoplastic lymphoproliferative disorders (nn-LPDs) temporally associated with vaccination have been reported, raising concerns about a potential immunologic link.</p><p><strong>Objective: </strong>To systematically review the literature on cases of CLs and related nn-LPDs occurring after COVID-19 vaccination, focusing on clinical features, subtype distribution, latency to onset, and proposed pathophysiological mechanisms.</p><p><strong>Methods: </strong>A systematic review was conducted according to PRISMA guidelines. Case reports and series describing new-onset or relapsed CLs or nn-LPDs temporally following SARS-CoV-2 vaccination were included. Demographic, clinical, histological, therapeutic and temporal data were extracted and analysed.</p><p><strong>Results: </strong>Fifteen manuscripts encompassing 35 cases met the inclusion criteria. Eighteen (51.4%) were histologically confirmed CLs, most commonly lymphomatoid papulosis (<i>n</i> = 9), followed by Sézary syndrome (<i>n</i> = 3) and mycosis fungoides (<i>n</i> = 2). The remaining 17 cases (48.6%) were classified as nn-LPDs, including cutaneous lymphoid hyperplasia, lymphomatoid reactions and CD4+ small/medium T-cell lymphoproliferative disorders. CD30 positivity was noted in 76.2% of the cases with available immunophenotyping. Most patients (80%) received the BNT162b2 (Pfizer-BioNTech) vaccine. In the 17 new-onset CLs, time to onset ranged from 3 to 42 days, with most cases clustering within 14 days.</p><p><strong>Conclusions: </strong>Most of the cases were low-grade T-cell CLs and nn-LPDs. Although a causal relationship cannot be established, the short latency observed in many new-onset cases raises the possibility that some patients may have harboured an undiagnosed disease, with vaccination acting as a trigger for clinical manifestation or for raised awareness. These findings support indeed the need for continued pharmacovigilance among clinicians, especially in patients with prior or latent lymphoproliferative conditions. Nevertheless, these extremely rare and indolent events should not alter the overall favourable risk-benefit profile of COVID-19 vaccination.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2026 ","pages":"4893577"},"PeriodicalIF":0.9,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13239182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes of Sonidegib in Vismodegib-Exposed Locally Advanced Basal Cell Carcinoma: Insights From a Multicenter Descriptive Study.","authors":"Alvaro Prados-Carmona, María Martínez-Pérez, J Pablo Velasco-Amador, Francisco M Almazán-Fernández, Ricardo Ruiz-Villaverde","doi":"10.1155/jskc/9016298","DOIUrl":"10.1155/jskc/9016298","url":null,"abstract":"<p><strong>Background: </strong>Locally advanced basal cell carcinoma represents a therapeutic challenge, especially if already exposed to hedgehog (Hh) pathway inhibitor (HPI) therapy. Effectiveness after switching to another HPI still requires exploration.</p><p><strong>Methods: </strong>This observational, descriptive study retrospectively evaluates the clinical outcomes of sonidegib in patients with vismodegib-treated locally advanced basal cell carcinoma in a real-world, multicenter cohort across nine centers. Twelve patients with histologically aggressive locally advanced basal cell carcinoma previously exposed to vismodegib for at least 3 months were analyzed. Each received sonidegib at a standard dosage. Treatment response was assessed clinically according to tumor size changes and classified as complete response (100% decrease), partial response (at least 50% decrease), stable disease (up to 20% increase or less than 50% decrease), or disease progression (at least 20% increase). Adverse events (AEs) were documented.</p><p><strong>Results: </strong>Two patients achieved complete clinical response, nine demonstrated partial response, and one exhibited disease progression. Disease control was achieved in 11 of the 12 patients (91.7%). No novel AEs have been documented, and they were managed through dose adjustments or temporary interruptions.</p><p><strong>Conclusion: </strong>These findings suggest that sonidegib could still show efficacy and may still serve as a viable second-line option after prior Hh pathway suspension.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2026 ","pages":"9016298"},"PeriodicalIF":0.9,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12880947/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146142684","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Severity of Sleep Disorders in Patients With Mycosis Fungoides: A Case-Control Study.","authors":"Ahmad Vafaeian, Aidin Shahilooy, Maryam Daneshpazhooh, Robabeh Abedini, Farid Mohamadi, Ala Ehsani, Hamidreza Mahmoudi","doi":"10.1155/jskc/5528328","DOIUrl":"10.1155/jskc/5528328","url":null,"abstract":"<p><strong>Introduction: </strong>Mycosis fungoides (MF) is the most common form of cutaneous T cell lymphoma. Given that MF is a rare disease, evidence regarding its impact on sleep and quality of life is limited; however, our study aims to evaluate this aspect.</p><p><strong>Patients and methods: </strong>In this case-control study, 72 patients with MF were enrolled in the case group, and 72 matched healthy individuals were enrolled in the control group. Data regarding sleep disturbances were collected and analyzed using the Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI) questionnaires. Poor sleep quality was defined as a score > 5.</p><p><strong>Results: </strong>The control and case groups had median scores of 5.12 ± 2.57 and 10.22 ± 3.75 by PSQI and 6.39 ± 4.86 and 16.28 ± 6.99 by ISI, respectively. Multiple logistic regression revealed a significant association between the study group and the prevalence of poor sleep quality, as measured by both the PSQI (<i>p</i> < 0.0001) and the ISI (<i>p</i> < 0.0001). However, age, sex, marital status, pruritus, disease stage and onset, and lesion locations were not found to be associated with poor sleep quality.</p><p><strong>Discussions: </strong>Both the severity and prevalence of sleep disorders were significantly higher in the patients compared to a matched healthy population. Due to the profound impact of sleep on quality of life and considering the high prevalence of sleep disorders in patients with MF, evaluating a patient's sleep quality could improve their quality of life. Therefore, professional treatment can be administered if sleep disorders are observed or suspected.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2025 ","pages":"5528328"},"PeriodicalIF":0.9,"publicationDate":"2025-12-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12767025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145912050","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic Potential of Baseline Eosinophils at the Initiation of Immune Checkpoint Inhibitor Treatment of Metastatic Melanoma: A Systematic Review and Meta-Analysis.","authors":"Thilo Gambichler, Jan Overbeck, Nessr Abu Rached, Laura Susok, Sera S Weyer-Fahlbusch","doi":"10.1155/jskc/2561307","DOIUrl":"10.1155/jskc/2561307","url":null,"abstract":"<p><p>Cutaneous melanoma (CM) remains a rapidly rising malignancy, with metastatic disease still carrying a limited 5-year survival. Immune checkpoint inhibitors (ICIs) have changed the treatment landscape, yet only a fraction of patients achieves durable benefit. Easily obtainable blood-based biomarkers are, therefore, needed to guide patient selection and prognostication. Eosinophilic granulocytes have emerged as potential modulators of antitumor immunity. In this systematic review and meta-analysis, we adhered to PRISMA guidelines and searched PubMed, Cochrane Library, and Scopus for studies published from 2011 onward that evaluated baseline peripheral eosinophil counts (absolute or percentage) as predictors of overall survival (OS) in advanced (stage III/IV) melanoma patients treated with ICI. Six cohort studies totaling 4.243 patients met inclusion criteria, each reporting hazard ratios (HRs) and 95% confidence intervals (CIs) in multivariable analyses for high versus low baseline eosinophil groups. Study quality was high (Newcastle-Ottawa Scale ≥ 7 stars), though selection biases were noted across all cohorts. A random-effects meta-analysis (DerSimonian-Laird method) initially yielded a pooled HR of 0.69 (95% CI: 0.36-1.30) for high versus low eosinophil counts, but heterogeneity was substantial (<i>I</i> ² = 77.8%, <i>p</i> < 0.001). Through Baujat and leave-one-out diagnostics, one study was identified as an influential outlier; its exclusion reduced heterogeneity down to 33.3% (<i>p</i>=0.20). Reanalysis of the remaining five studies (<i>n</i> = 4.158) demonstrated a significant survival advantage for patients with elevated baseline eosinophils (HR: 0.51 and 95% CI: 0.39-0.66; <i>p</i> < 0.001). Funnel plot symmetry and a nonsignificant Egger's test (<i>p</i>=0.27) indicated no evidence of publication bias. These findings support baseline peripheral eosinophil count as a cost-effective, readily available biomarker associated with improved OS under ICI therapy in advanced melanoma. However, prospective studies with standardized eosinophil thresholds, comprehensive covariate adjustment, and integrated mechanistic analyses are warranted to validate and operationalize this marker for patient stratification in clinical practice.</p>","PeriodicalId":17172,"journal":{"name":"Journal of Skin Cancer","volume":"2025 ","pages":"2561307"},"PeriodicalIF":2.0,"publicationDate":"2025-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12682457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145707984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}